| Literature DB >> 31545906 |
Eric Mühlberg1, Florian Umstätter1, Christian Kleist1, Cornelius Domhan2, Walter Mier1, Philipp Uhl1.
Abstract
The emergence of multidrug-resistant bacteria demands innovations in the development of new antibiotics. For decades, the glycopeptide antibiotic vancomycin has been considered as the "last resort" treatment of severe infections caused by Gram-positive bacteria. Since the discovery of the first vancomycin-resistant enterococci strains in the late 1980s, the number of resistances has been steadily rising, with often life-threatening consequences. As an alternative to the generation of completely new substances, novel approaches focus on structural modifications of established antibiotics such as vancomycin to overcome these resistances. Here, we provide an overview of several promising modifications of vancomycin to restore its efficacy against vancomycin-resistant enterococci.Entities:
Keywords: antibiotics; antibiotiques; bactérie multirésistante aux médicaments; enterococci; entérocoques; modification structurale; multidrug-resistant bacteria; structural modification; vancomycin; vancomycine
Mesh:
Substances:
Year: 2019 PMID: 31545906 DOI: 10.1139/cjm-2019-0309
Source DB: PubMed Journal: Can J Microbiol ISSN: 0008-4166 Impact factor: 2.419